An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs BI 2536 (Primary)
- Indications Anaplastic large cell lymphoma; B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 04 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2012 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
- 28 Jul 2006 New trial record.